In this issue:
Low-dose decitabine ±CEG in elderly MDS
COVID-19 in ALL patients: first vs. second pandemic wave
Azacitidine vs. allogeneic SCT in elderly advanced MDS
Romyelocel-L for reducing infection during induction chemotherapy for AML
Biosimilar vs. originator eculizumab in PNH
Bortezomib + dexamethasone as first-line therapy for POEMS
Omidubicel vs. standard myeloablative umbilical cord blood transplantation
NRM in patients with chronic GVHD
Allogeneic blood vs. marrow transplantation in myelofibrosis
Lenalidomide + dexamethasone in relapsed/refractory light-chain amyloidosis
Please login below to download this issue (PDF)